This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
British Journal of Cancer Open Access 05 September 2017
-
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma
Oncology and Therapy Open Access 02 November 2016
-
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
British Journal of Cancer Open Access 22 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095–1110.
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962–2972.
Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269–3276.
Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA . Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41–51.
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008–5014.
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934–1939.
Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Sullivan D et al. A Phase 1/2 Multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annu Meet Abstr 2010; 116: 864.
Leleu X, Attal M, Moreau P, Duhamel A, Fermand JP, Michalet M et al. Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02. ASH Annu Meet Abstr 2010; 116: 859.
Lacy M, Mandrekar S, Gertz MAA, Hayman SR, Short KD, Buadi F et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. ASH Annu Meet Abstr 2010; 116: 863.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2011; doi: 10.1038/leu.2011.196.
Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009; 84: 657–660.
Madan S, Lacy M, Dispenzieri A, Gertz M, Buadi F, Hayman SR et al. Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma. ASH Annu Meet Abstr 2010; 116: 1964.
Acknowledgements
This study was supported in part by the Paul Calabresi Award for Clinical Oncology, CA90628 (SKK) and the Hematologic Malignancies Program (Mayo Clinic).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MQL has received research funding from Celgene; JM has receivedresearch funding from Celgene, Onyx, Novartis; AD has received research funding from Celgene and Travel award binding site; MAG has received Honoraria from Celgene, Millenium, Neotope Eisai, Inc., Lilly Research Laboratories, Optum Health Education, Research to Practice, Physician's Education Resource and Amgen, Inc.; and SKK has received research funding from Celegene, Genzyme, Millenium, Novartis, Bayer, Merck and Cephalon, and has participated in Advisory board for Genzyme. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sinha, S., Lacy, M., Mikhael, J. et al. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 26, 839–841 (2012). https://doi.org/10.1038/leu.2011.279
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.279
This article is cited by
-
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
British Journal of Cancer (2017)
-
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
British Journal of Cancer (2016)
-
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma
Oncology and Therapy (2016)
-
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
Blood Cancer Journal (2013)
-
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
Leukemia (2013)